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Abstract
JCV infection occurs early in childhood and last throughout life. JCV has been associated to colorectal cancer and
might contribute to the cancer phenotype by several mechanisms. Among JCV proteins, particularly two of them,
large T-antigen and agnoprotein, can interfere with cell cycle control and genomic instability mechanisms, but
other viral proteins might also contribute to the process. Part of viral DNA sequences are detected in carcinoma
lesions, but less frequently in adenomas, and not in the normal surrounding tissue, suggesting they are integrated
in the host cell genome and these integrations have been selected; in addition viral integration can cause a gene,
or chromosomal damage. The inflammatory infiltration caused by a local chronic viral infection in the intestine can
contribute to the selection and expansion of a tumor prone cell in a cytokine rich microenvironment. JCV may not
be the cause of colorectal cancer, but it can be a relevant risk factor and able to facilitate progression at one or
several stages in tumor progression. JCV transient effects might lead to selective expansion of tumor cells. Since
there is not a direct cause and effect relationship, JCV infection may be an alternative to low frequency cancer pre-
disposition genes.
Cancer is a multifactor disease that its progression is
determined by several genetic alterations, which are
most likely sequentially selected for their contribution to
the tumor phenotype [1]. This phenotypic complexity
makes difficult to determine the specific roles for biolo-
gical agents that might be considered carcinogenic, and
even more difficult to determine their causality, or
implication at a particular stage in disease progression.
Among the exogenous agents associated to cancer initia-
tion or progression are chemicals, which are single
molecules with a specific effect; and some infectious
agents, including viruses and bacteria.
Infectious diseases are acquiring relevance as impor-
tant pathogenic elements in human cancer, since almost
one fifth of human cancers are associated with infec-
tious agent, either bacteria or viruses, particularly in the
gastrointestinal tract [2], but do not represent main-
stream oncologic research. The development of several
types of human cancers can be triggered by the
exposure to different infectious agents, viruses or bac-
teria, such as Human Papilloma Virus (HPV) infection
associated to cervical carcinoma [3], hepatitis B virus to
liver carcinoma [4], Epstein-Barr virus to Burkitt lym-
phomas [5], HTVL-1 to ATL [6], Helicobacter pylori to
gastric carcinoma [7] and more recently a human retro-
virus, XMRV, has been associated to sporadic prostate
cancer [8-10]. More recently, it has been reported the
association between the development of lower gastroin-
testinal tract neoplasias and infectious agents [7], such
as between colorectal cancer (CRC) and JCV infection.
J C Vi sav i r u sv e r yw e l la d a pted to humans, thus its
widespread infection and adaptation to humans compli-
cates the determination of its etiologic contribution to
cancer development, and it has also been associated to
some neurodegenerative diseases [11].
A chronic infection might be a non genetic alternative
to cancer predisposing genes. The mechanistic role of
infectious agents is even more complex, because they
might contribute in several different ways to oncogen-
esis. Infections can also play a role at different stages in
tumor progression, from initiators to promoters of the
process, depending on the phenotypic aspect to which
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consequence of the host response to chronic infection.
Thus, causality of infectious agents in cancer is some-
what more difficult to demonstrate.
The viral contribution to oncogenesis has to be
addressed by determining how the viral life cycle and
the host response, including their alterations, can be
integrated within the multistep process of tumor devel-
opment. Viruses that are well adapted to humans can
participate in oncogenesis process because they have not
undergone a negative evolutionary pressure, since cancer
develops at an age well above the median age of humans
till the twentieth century, However, the benefits of inter-
fering or preventing infectious agents implicated in can-
cer is very large as demonstrated in hepatic, gastric and
cervical carcinomas [2].
Colorectal cancer (CRC) is the third most common
tumor in women and the fourth in man; representing
annually one million new cases worldwide, and more
than 500.000 deaths are caused by this malignant dis-
ease [12]. Most colorectal cancers are sporadic in their
origin and associated to different risk factors, such as a
diet rich in fat and animal protein intake [13].
JCV infection in human population
The extent of the exposure to JCV infection is indirectly
known by seroprevalence rates detected in different
populations throughout the world, ranging from 44 to
90% in the USA, UK, Germany, Brazil and Japan
[7,14,15]; all indicating it is widespread and common.
The infection may occur by fecal contamination and is
usually persistent and sub clinical, but is reactivated
under conditions of immunosuppression, such as in
patients with AIDS, and JCV can also emerge from
latency and become a lytic infection causing progressive
multifocal leukoencephalopathy (PML) [16]. JCV infec-
tion occurs relatively early during childhood and seropo-
sitivity increases with age, and may be as high as 50% by
the age of 10 [17]. Infection appears to occur through
the gastrointestinal tract [18-20], but also it has been
detected in the respiratory tract raising the possibility of
an oral-fecal transmission [21,22]. The detection of anti-
bodies from childhood to adults suggests that these anti-
bodies are unlikely to be protective, however they are a
clear indicator of exposure, probably multiple or sus-
tained, to JCV. The persistence of seropositivity does
not mean that individual patients have an active infec-
tion at the moment, or that harbor viral DNA or latent
virus in some cells. The antibody mediated immune
response is unlikely to be protective, and control of JCV
infection is more probably performed by T-cell
mediated responses, if successful [23]. It would be inter-
esting to determine if tumor-infiltrating lymphocytes
from colon carcinoma can recognize and react with JCV
infected cells.
Alternatively, urinary secretion of JCV has been used
as an alternative detection method. JCV was present in
24% of the samples out of 498 healthy individuals, and
the proportion increased with age [24]. However, in
immunocompromised patients there is a significant
increase in JCV viruria, although it does not correspond
with the level of immunosuppression, suggesting the
presence of a subclinical infection that might require
additional factors to be reactivated [25]. These data indi-
cate that most people have been exposed for some time
to this virus in order to generate an immune reaction.
In cancer patients viruria was detected in up to 70 per-
cent of the cases, but viral DNA could not be detected
in carcinoma tissue; but this apparent discrepancy might
have a methodological explanation, as primer selection
may not be suitable in case of partial loss of viral DNA,
or viruses might transiently contribute to a particular
stage of tumor progression [14]; particularly since later
several studies were able to detect viral DNA in carci-
noma samples [15,26].
The JC virus
T h ep o l y o m a v i r u s e sf a m i l yc o m p r i s e sS V 4 0 ,J C Va n d
BKV viruses, the primate SV40 virus is the reference
member, while BKV and JCV are much poorly charac-
terized, and mostly done with SV40 specific cross-reac-
tive reagents [27]. Despite their isolation from humans,
their role in human pathology is far from clear for both
JCV and BKV. JCV is a nonenveloped virus with dou-
ble-stranded DNA that forms minichromosomes with
cellular histones. The JCV early region encodes two
oncoproteins, large T antigen (T-Ag) and small t (t-Ag)
antigen and the late region encodes three capsid pro-
teins (VP1, VP2 and VP3) and a small regulatory protein
(Agnoprotein). The viral DNA is packed as a non-envel-
oped virus in a virion composed of 72 pentamers of the
major VP1 capsid protein, that also includes one unit of
the minor VP2 and VP3 proteins [11]. These early viral
proteins have a high transformation and oncogenic
potential in experimental systems [28,29]. There are two
possible outcomes to JCV infection: permissive cells, as
oligodendrocytes, are able to support viral DNA replica-
tion resulting in a lytic infection; in nonpermissive cells,
as those of the colorectal epithelium, resulting in silent
or abortive infection, or probably in cell transformation
and cancer [28]. Despite these evidences, the role of
JCV in human malignancies, and of its oncoproteins in
promoting transformation of cells in vitro and in vivo, is
still far from clear. JCV does not infect experimental
animals, and its roles have been implied by analogy to
SV40 [30].
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logical diseases, such as progressive multifocal leukoence-
phalopathy have been associated to JC virus [11,31].
Initial studies suggested that the transforming ability of
JCV was limited to specific neural cell types, and that this
property mapped to the noncoding regulatory sequence
in the origin of DNA replication, but no neural tumor
has been associated to JCV. However, JCV can also infect
and transform different cell-types in culture and is highly
oncogenic in several laboratory animal models [32].
F u r t h e r m o r e ,t h e r ei se v i d e n c ef o rt h ep r e s e n c eo ft h e
JCV genome in a broad range of human cell types and
tissues. For example, the JCV genome has been detected
in tonsillar stromal cells, B lymphoid cells, kidney epithe-
lial cells, and upper and lower parts of the gastrointest-
inal tract, including the mucosa of the colon, which is
considered as the natural human reservoir [18].
In addition, the JCV genome has variant forms which
might behave differently from an oncogenic point of view.
The Mad-1 strain, which lacks 98 nucleotides repeats in
its transcriptional regulatory region, was the only one
detected in colon carcinomas from California patients
[33], but no functional study on the characteristics of this
regulatory region has been performed. More recently in
another study performed in Taiwan, most CRC cases
appeared to have the JCV-CY genotype [15], which is also
the dominant genotype in this population, although the
Mad-1 strain was also detected [15]. Thus it is not clear if
this strain association reflects the viral types circulating in
different geographical areas, or if there are particular
strains more strongly associated to carcinomas.
JCV DNA in normal, benign and malignant
colorectal lesions
JCV DNA sequences and proteins have been detected in
a broad range of human tumors of glial and non-glial
origin, including gliomas, ependymomas and medullo-
blastomas, as well as in several non-neural clinical speci-
mens of upper and lower gastrointestinal tumors, such
as colorectal cancer (CRC) [7], suggesting they can
i n f e c taw i d er a n g eo fc e l lt y p e s ,b u tt h er o l eo fJ C Vi n
human malignancies is still unclear. A very important
issue is to determine whether the presence of JCV pre-
sents any difference between tumor of different grades
and its normal surrounding mucosa. Very few studies
have been performed in this context, but a picture of
the situation is emerging from three independent studies
in Japan [26], Taiwan [15] and South Korea [34]. Rem-
nant JCV large- T DNA was detected in 28-80% of the
cases, but protein was only detected in 16% of the carci-
nomas. Also the frequency is lower in benign adenomas,
and negative in normal surrounding tissue [26]. DNA
corresponding to agnoprotein and VP genes was not
detected suggesting they were deleted [34]. More
importantly in this study no viral DNA sequences were
detected in the adjacent normal tissues [34]. The general
findings are consistent among these three studies, and
the variation in frequency is likely to be a consequence
of the different primers used for viral DNA detection.
However, a similar and earlier study in the USA was not
consistent with this observation, but in that case there
was no microdissection of the CRC biopsies and primers
were different [14]. In none of these studies there is any
indication about the JCV strain implicated.
The variability in JCV detection suggests that in an
infected colon, in some cells there might be integration
with partial loss of JCV DNA, which may have a patho-
genic role in cancer development, probably permitting
additional events that will lead to cancer progression by
permitting selection of a cell subpopulation. When
human CRC samples were grown as xenographs in nude
mice that permit expansion of the cancer cell popula-
tion, all of them resulted positive for JCV [18], suggest-
ing that the cell subpopulation containing JCV might be
selected for its growth and adaptation characteristics. In
a way, this situation is reminiscent of what occurs in
cervical carcinoma, in which most HPV infections and
lesions regress, but some progress, and cervical carcino-
mas have remnant viral DNA coding for some viral pro-
teins, E6 and E7, but the other HPV proteins are not
expressed in these carcinomas [3]; these viral proteins
participate in the oncogenic process, but clearly need
additional, non virally related events [35,36].
Multiple effects of JCV large T- antigen in host
cells
JCV is able to translate its early proteins, namely LT-Ag,
in order to trigger the progression of the cell cycle to
the phase S in host-cell [29,37]. JCV LT-Ag has the abil-
ity to interact with p53; thus it is possible that in some
cells this interference with p53 [38], which also inter-
feres with viral replication [38], might allow the occur-
rence of additional genetic damage representing a step
forward in colon carcinogenesis [39,40]. In addition,
there are several additional mechanisms by which LT-
Ag can also interfere with cellular functions. JCV LT-Ag
can interact with proteins involved in cellular regulation
such as IRS-1 (Insulin receptor substrate-1), a major
protein of the insulin-like growth factor I receptor (IGF-
IR) signaling pathway, which is activated and translo-
cated to the nucleus in the presence of LT-Ag [41].
Activated IRS1, is an adaptor in the cell response to
insulin, activating PI3K, implicated in cell survival [42],
and proliferation signals [43]. Thus at the same time it
will permit survival and expansion of a JCV containing
subpopulation. Some polymorphisms of the IRS1 gene
have been associated with an increased risk of colorectal
cancer [44]. These signaling effects associated to LT-Ag
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facilitating the expansion of a specific subpopulation,
perhaps already pretumoral. LT-Ag can also inhibit
homologous recombination directed DNA repair (HRR)
causing DNA damage, mechanistically by its interaction
with IRS1 [45], which also interacts with Rad51 at loca-
tions of damaged DNA [46,47], and thus may contribute
to generate some genetic instability in cells containing
JCV [48]. JCV also by a hit and run mechanism, that is
a transient effect, is able to trigger genetic instability by
interacting with p53 and b-catenin in colonic cells,
which is detected only in the first seven days after infec-
tion [49]. LT-Ag also contributes to the stabilization of
b-catenin by a novel mechanism mediated by the small
GTPase Rac1 [50]. b-catenin is an integral component
of the Wnt signaling pathway whose stabilization is
associated with increased transcription of genes that
regulate cellular proliferation, e.g., c-myc and cyclin D1,
despite the fact that the functional consequence of this
JCV interaction in cancer development remains to be
elucidated. LT-Ag interacts with b-catenin [51], and b-
catenin implication in colorectal cancer is well known
[52,53]. This observation is supported by reports on the
involvement of Wnt signaling pathway [54] and c-myc
[55] in colorectal carcinogenesis. If the effect persists for
some time in infected cells harboring JCV, they might
contribute to expand a cell subpopulation that later
might give rise to cancer.
Effects of JCV agnoprotein in host cells
JCV expresses a small 71 aminoacids protein, known as
agnoprotein, which is a regulatory protein that can
repress the expression of p21WAF-1/Cip1, a regulator
of the cell cycle that inhibits the activation of cyclin/
CDK complexes and releases E2F transcription factor
from phospho-Rb, thus agnoprotein removes an inhibi-
tor of cell cycle progression. Consequently, p21WAF-1/
Cip1 and E2F stimulate several proteins, the function of
which is essential for cell cycle progression and rapid
cell proliferation [56]. This role is in some aspects remi-
niscent of the action of E6 in cervical carcinogenesis,
where the elimination of p53 also results in lack of
induction of p21 [57,58], and permits cell cycle progres-
sion. Agnoprotein can also alter the expression of Ku70
and Ku80 [56], two proteins implicated in DNA repair
[59,60], and thus indirectly contribute to a potential
accumulation of genetic damage. Furthermore, agnopro-
tein can also interact with the YB-1 transcription factor
[61], a factor that when is downregulated results in an
induction of apoptosis [62] by regulating the mTOR/Akt
pathway [63]. This YB-1 transcription factor can also
modulate the response to the erbB2 receptor [64], and
contribute prevention of premature senescence [65]. In
addition YB-1 also controls some chemokine ligand [66]
and metaloprotease gene expression, such as MMP13
[67], two types of proteins that can have an important
role in carcinogenesis. YB-1 has been shown to have a
predictive value in breast cancer patients identifying
those with a poorer prognosis [68,69]. However, there is
no systematic study of the presence and role of this
viral protein, or of YB-1, at different stages of CRC pro-
gression. Agnoprotein has been shown to inhibit differ-
entiation of oligiodendrocytes [70]; if a similar effect
could be induced in colonic epithelium, it will be an
additional contributing factor towards tumorigenesis.
But a detailed study of agnoprotein presence in biopsies
representing different stages of CCR has not yet been
performed.
Tumor immune microenvironment
Another important component of tumorigenesis is
represented by the tumor microenvironment, where
local cytokines that can play a stimulatory role. These
cytokines may originate either in the tumor itself or in
the local inflammatory infiltrate, and can activate JCV
gene expression by a cis-acting transcription factor,
E g r 1 ;af a c t o rw h i c hm o s t l ya c t i v a t e st h el a t ep r o m o t e r ,
and affects VP1 expression and viral replication [71].
The expression of this capsid protein can also trigger an
inflammatory and immune reaction, with the corre-
sponding local availability of several additional cyto-
kines. This viral reactivation might also result in viral
production, dissemination, and reinfection of neighbor-
ing cells. This mechanism could be important for main-
tenance or reactivation of a local subclinical infection.
In this context it is important the recent observation
that patients which have undergone liver transplantation
have an increased risk of colorectal cancer due to reacti-
vation of JCV, probably as a result of immunosuppres-
sive treatment [72].
Additional aspects in JCV associated oncogenesis
Another mechanism by which JCV can contribute to
colorectal carcinogenesis might, in some aspects, be
similar to the role of human papillomaviruses (HPV) in
cervical carcinoma [35,36]. Viral DNA integration has
only been partially addressed in cervical cancer asso-
ciated to HPV [73], and the chromosomal location of
viral integration sites coincides with those of fragile
chromosome sites [74], and with translocation break-
points already detected in other types of carcinomas
[36,75], although the cellular genes affected are not
known. If the JCV infection is persistent, then there is a
good probability that JCV DNA might integrate in the
host cell genome, and some of the viral DNA remains
in a manner similar to what occurs with HPV in cervical
carcinoma [74]. JCV DNA integration appears to be a
common observation in CRC when this issue has been
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properly addressed. This integration, if demonstrated,
can explain why in some cases JCV is not detected. Inte-
grated JCV DNA may be an important and irreversible
component in the pathogenesis of CRC. In that way a
cell population can harbor viral DNA from which some
viral genes can be expressed with an altered regulation.
The penetrance of the remaining viral gene and its level
of expression might condition the risk of developing
cancer. Also other viral genes might be lost, particularly
those of the capsid, thus an immune reaction against
them will not be effective.
Roles that JCV can play in colorectal cancer
The role of JCV in cancer does not fit within a classical
concept of direct relation between cause and effect as it
is for other infectious diseases and neither as a simple
risk factor as applied to chemical or physical carcino-
gens. JCV might participate in different ways in the
pathogenesis of colorectal cancer; both direct and indir-
ect (Figure 1). This situation is a consequence of the
complexity of the mechanisms contributing to cancer
phenotype, which have many different phases, ranging
from initiation, promotion, morphological progression
with different biological characteristics, to tumor main-
tenance and dissemination. Thus, to pinpoint a unique
mechanism of action for a virus represents a very sim-
plistic approach to the problem. Some of the effects
induced by JCV might be transitory and contribute to
tumor progression at a particular stage of tumor pro-
gression. For example, a transitory genetic instability
will permit generation of generic damage that might
facilitate progression, but once it occurs, it is no longer
needed. Other contributing factors are viral protein
expression or viral DNA integration that might be
i m p o r t a n to n l ya ts o m es t e ps in cancer progression.
Also chronic infection is known to be a bad prognostic
indicator due to the immune cell infiltration and genera-
tion of a microenvironment very rich in cytokines,
which can promote expansion of premalignant or malig-
nant cells, not necessarily with JCV, that will facilitate
cancer cell growth and dissemination. Some of the
effects might be transient and this will further compli-
cate establishing a direct relation between JCV and
CRC. In any case there is no evidence, epidemiological
or physiopathological, to rule out a role for JCV in col-
orectal carcinogenesis, even if its role is still undefined;
but on the contrary there is enough information point-
ing to roles that remain to be conclusively established.
Outstanding issues and future prospects
The role of any virus as a causal agent in cancer should
not be considered simply as a direct cause-effect. The
virus should be considered as a complex agent with
potentially multiple and varying effects. In order to
properly establish if JCV is indeed an important risk
Figure 1 Multistep colorectal carcinogenesis. Diagram illustrating the different components by which JCV can participate in multistep
colorectal oncogenesis, either in a transient or irreversible way.
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need to be properly addressed.
1. Establish conclusively that CRC patients, in a signif-
icant number of cases, have been exposed to this virus,
and of which an indirect marker will be the presence of
specific antibodies.
2. Improve detection of viral DNA by using standar-
dized sets of primers for each of the relevant viral genes,
as well as strain identification. This should also contri-
bute to establish the potential and irreversible integra-
tion of remnant JCV DNA in cancer cells, and permit
identification of significant differences among malignant,
benign or normal surrounding tissue.
3. Correlate JCV DNA presence with other mutations
known to sequentially occur in CRC, and its association
with other known risk factors.
4. Identification of viral protein expression at different
stages of colorectal cancer progression. For this aim
development of better specific antibodies for JCV pro-
teins are necessary.
5. Characterize the host immune response to JCV in
order to manipulate it and develop strategies to eradi-
cate the virus from the human population. In particular
determine the role T-cell responses, since the natural
antibody response does not seem to be protective.
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